Drug Profile
MSB 0010445
Alternative Names: EMD 521873; MSB0010445; NHS-IL2; NHS-IL2-LT; SelectikineLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator EMD Serono; Merck Serono
- Class Antineoplastics; Cytokines; Drug conjugates; Immunoconjugates; Recombinant fusion proteins
- Mechanism of Action Interleukin-2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 30 Nov 2013 Phase-II clinical trials in Malignant melanoma (second-line therapy or greater, late-stage disease) in USA (IV)
- 25 Oct 2013 EMD Serono plans a phase IIa trial for Malignant melanoma (unresectable or metastatic disease) in USA (NCT01973608)
- 31 Jan 2012 Merck completes a phase I trial in Non-Hodgkin's lymphoma and Solid tumours in Germany and Switzerland (NCT00879866)